Clinical Trials
4 trialsNCT06638931 2026-04-15
ANTARES
Instituto do Cancer do Estado de São Paulo
Phase 2 Recruiting
NCT04061980 2026-04-13
Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer
Providence Health & Services
Phase 2 Active not recruiting
NCT07419932 2026-02-19
NeoLATC
Fujian Medical University
Recruiting
NCT03246958 2025-06-19
Nivolumab Plus Ipilimumab in Thyroid Cancer
Dana-Farber Cancer Institute
Phase 2 Completed